Bioneer Corporation (064550.KQ)
KRW 19520.0
(-3.84%)
KRW 19520.0
(-3.84%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 44.63 Billion KRW | 60.17% |
| 2022 | 27.87 Billion KRW | 32.58% |
| 2021 | 21.02 Billion KRW | 55.28% |
| 2020 | 13.53 Billion KRW | -49.89% |
| 2019 | 27.01 Billion KRW | 46.51% |
| 2018 | 18.44 Billion KRW | -2.33% |
| 2017 | 18.88 Billion KRW | -24.15% |
| 2016 | 24.89 Billion KRW | -3.27% |
| 2015 | 25.73 Billion KRW | -2.44% |
| 2014 | 26.37 Billion KRW | -11.32% |
| 2013 | 29.74 Billion KRW | 0.0% |
| 2012 | - KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 55.88 Billion KRW | 0.85% |
| 2024 Q1 | 55.41 Billion KRW | 24.14% |
| 2023 Q3 | 35.39 Billion KRW | 16.68% |
| 2023 Q4 | 44.63 Billion KRW | 26.12% |
| 2023 Q1 | 28.89 Billion KRW | 3.68% |
| 2023 FY | 44.63 Billion KRW | 60.17% |
| 2023 Q2 | 30.33 Billion KRW | 4.98% |
| 2022 Q3 | 28.15 Billion KRW | 22.28% |
| 2022 FY | 27.87 Billion KRW | 32.58% |
| 2022 Q4 | 27.87 Billion KRW | -1.01% |
| 2022 Q2 | 23.02 Billion KRW | 6.55% |
| 2022 Q1 | 21.6 Billion KRW | 2.8% |
| 2021 Q1 | 28.35 Billion KRW | 122.14% |
| 2021 Q4 | 21.02 Billion KRW | -12.54% |
| 2021 FY | 21.02 Billion KRW | 55.28% |
| 2021 Q3 | 24.03 Billion KRW | -16.18% |
| 2021 Q2 | 28.67 Billion KRW | 1.12% |
| 2020 FY | 13.53 Billion KRW | -49.89% |
| 2020 Q2 | 22.35 Billion KRW | -16.05% |
| 2020 Q3 | 22.75 Billion KRW | 1.78% |
| 2020 Q4 | 12.76 Billion KRW | -43.91% |
| 2020 Q1 | 26.63 Billion KRW | -0.31% |
| 2019 Q1 | 18.54 Billion KRW | 0.54% |
| 2019 Q2 | 18.1 Billion KRW | -2.33% |
| 2019 Q3 | 18 Billion KRW | -0.58% |
| 2019 FY | 27.01 Billion KRW | 46.51% |
| 2019 Q4 | 26.71 Billion KRW | 48.38% |
| 2018 Q1 | 18.78 Billion KRW | -0.49% |
| 2018 FY | 18.44 Billion KRW | -2.33% |
| 2018 Q4 | 18.44 Billion KRW | -46.77% |
| 2018 Q3 | 34.64 Billion KRW | -1.46% |
| 2018 Q2 | 35.15 Billion KRW | 87.12% |
| 2017 FY | 18.88 Billion KRW | -24.15% |
| 2017 Q4 | 18.88 Billion KRW | -0.48% |
| 2017 Q3 | 18.97 Billion KRW | -7.96% |
| 2017 Q2 | 20.61 Billion KRW | -17.58% |
| 2017 Q1 | 25 Billion KRW | 0.48% |
| 2016 Q2 | 25.23 Billion KRW | -2.18% |
| 2016 FY | 24.89 Billion KRW | -3.27% |
| 2016 Q3 | 25.34 Billion KRW | 0.44% |
| 2016 Q4 | 24.89 Billion KRW | -1.81% |
| 2016 Q1 | 25.8 Billion KRW | 0.26% |
| 2015 Q1 | 27.21 Billion KRW | 3.17% |
| 2015 Q4 | 25.73 Billion KRW | 1.42% |
| 2015 Q3 | 25.37 Billion KRW | -9.51% |
| 2015 Q2 | 28.04 Billion KRW | 3.04% |
| 2015 FY | 25.73 Billion KRW | -2.44% |
| 2014 Q2 | 30.01 Billion KRW | 4.52% |
| 2014 Q3 | 27.03 Billion KRW | -9.92% |
| 2014 Q4 | 26.37 Billion KRW | -2.43% |
| 2014 Q1 | 28.71 Billion KRW | -3.46% |
| 2014 FY | 26.37 Billion KRW | -11.32% |
| 2013 FY | 29.74 Billion KRW | 0.0% |
| 2013 Q4 | 29.74 Billion KRW | 2.82% |
| 2013 Q3 | 28.93 Billion KRW | -7.61% |
| 2013 Q2 | 31.31 Billion KRW | 8.2% |
| 2013 Q1 | 28.94 Billion KRW | 0.0% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q4 | - KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| HLB Co., Ltd. | 62.7 Billion KRW | 28.81% |
| iNtRON Biotechnology, Inc. | 402.9 Million KRW | -10979.378% |
| BINEX Co., Ltd. | 53.5 Billion KRW | 16.572% |
| Anterogen.Co.,Ltd. | 9.74 Billion KRW | -358.296% |
| MEDIPOST Co., Ltd. | 52.33 Billion KRW | 14.708% |
| CrystalGenomics, Inc. | 32 Billion USD | -39.486% |
| Helixmith Co., Ltd | 20.22 Billion KRW | -120.687% |
| Chabiotech Co.,Ltd. | 449.63 Billion KRW | 90.072% |
| Medy-Tox Inc. | 82.83 Billion KRW | 46.107% |
| Peptron, Inc. | 9.13 Billion KRW | -388.776% |
| Amicogen, Inc. | 149.59 Billion KRW | 70.16% |
| Genexine, Inc. | 67.42 Billion KRW | 33.795% |
| HLB Therapeutics Co.,Ltd. | 10.02 Billion KRW | -345.403% |
| LegoChem Biosciences, Inc. | 12.64 Billion KRW | -253.054% |
| ALTEOGEN Inc. | 83.76 Billion KRW | 46.711% |
| PharmaResearch Co., Ltd. | 34.3 Billion KRW | -30.12% |
| SillaJen, Inc. | 9.69 Billion KRW | -360.365% |
| JETEMA, Co., Ltd. | 130.49 Billion KRW | 65.792% |
| OliX Pharmaceuticals,Inc | 39.35 Billion KRW | -13.422% |
| Genomictree Inc. | 1.83 Billion KRW | -2333.144% |
| MedPacto, Inc. | 8.6 Billion KRW | -418.82% |
| D&D Pharmatech | 8.13 Billion KRW | -448.785% |
| EASY BIO,Inc. | 82.27 Billion KRW | 45.745% |
| GI Innovation, Inc. | 3.72 Billion KRW | -1099.728% |